"CD56 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
| Descriptor ID |
D019002
|
| MeSH Number(s) |
D12.776.395.550.200.250.520.156 D12.776.543.550.200.250.520.156 D23.050.301.264.894.156 D23.050.301.350.250.520.156 D23.101.100.894.156
|
| Concept/Terms |
CD56 Antigen- CD56 Antigen
- Antigen, CD56
- Leu-19 Antigen
- Antigen, Leu-19
- Leu 19 Antigen
- Antigens, CD56
- NKH-1 Antigen
- Antigen, NKH-1
- NKH 1 Antigen
- CD56 Antigens
|
Below are MeSH descriptors whose meaning is more general than "CD56 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Cell Adhesion Molecules [D12.776.395.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.395.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.395.550.200.250.520]
- CD56 Antigen [D12.776.395.550.200.250.520.156]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Cell Adhesion Molecules [D12.776.543.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.543.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.543.550.200.250.520]
- CD56 Antigen [D12.776.543.550.200.250.520.156]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD56 Antigen [D23.050.301.264.894.156]
- Cell Adhesion Molecules [D23.050.301.350]
- Cell Adhesion Molecules, Neuronal [D23.050.301.350.250]
- Neural Cell Adhesion Molecules [D23.050.301.350.250.520]
- CD56 Antigen [D23.050.301.350.250.520.156]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD56 Antigen [D23.101.100.894.156]
Below are MeSH descriptors whose meaning is more specific than "CD56 Antigen".
This graph shows the total number of publications written about "CD56 Antigen" by people in this website by year, and whether "CD56 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD56 Antigen" by people in Profiles.
-
Genomic and Transcriptomic Profiling of Digital Papillary Adenocarcinomas Reveals Alterations in Matrix?Remodeling and Metabolic Genes. J Cutan Pathol. 2025 Apr; 52(4):309-316.
-
Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021 11; 53(11):1543-1552.
-
Cerebrospinal fluid NCAM-1 concentration is associated with neurodevelopmental outcome in post-hemorrhagic hydrocephalus of prematurity. PLoS One. 2021; 16(3):e0247749.
-
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol. 2021 07; 34(7):1358-1366.
-
CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia? Blood. 2020 09 24; 136(13):1565.
-
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 12 15; 126(24):5303-5310.
-
CD56 regulates human NK cell cytotoxicity through Pyk2. Elife. 2020 06 08; 9.
-
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
-
Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochem Biophys Res Commun. 2018 10 20; 505(1):181-186.
-
CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity. 2018 09 18; 49(3):464-476.e4.